American Society of Breast Surgeons Endorses Cryoablation for Early-Stage Breast Cancer Treatments

Recent ASBrS Guidance on Cryoablation

The American Society of Breast Surgeons (ASBrS) has made significant updates in its 2026 Resource Guide, wherein it notably endorses cryoablation as a therapeutic option for patients with low-risk, early-stage breast cancer. This comes as a welcomed development for patients aged 70 and above, particularly those with tumors measuring 1.5 cm or less, who have opted for adjuvant endocrine therapy.

Overview of Cryoablation

IceCure Medical Ltd. has been at the forefront of developing minimally invasive cryoablation technology, specifically with its ProSense® system designed to freeze tumors, offering an alternative to traditional surgical methods. With FDA clearance achieved in October 2025 for treating low-risk breast cancer, this innovative approach symbolizes a paradigm shift in breast cancer care.

ASBrS's Updated Recommendations

According to ASBrS's newly revised guidelines, cryoablation is now recommended as a safe, effective, and cosmetically favorable treatment. This reflects the organization's commitment to integrating new clinical evidence with established best practices, paving the way for broader implementation of cryoablation in clinical settings. Eyal Shamir, IceCure's Chief Executive Officer, expressed optimism about this recognition, pointing out that it underscores cryoablation’s role as a progressive choice in breast cancer management prioritizing both patient outcomes and aesthetic considerations.

Moreover, the comprehensive treatment plans suggested by ASBrS stress the importance of a multidisciplinary approach, ensuring that patients receive tailored care that considers their individual needs and circumstances. Shad Good, IceCure’s Vice President of Sales for North America, emphasized the importance of this new guidance in boosting confidence among patients and breast surgeons about cryoablation.

The Clinical Landscape

Recent studies show that cryoablation could cater to an estimated U.S. breast cryoablation population of about 200,000 women annually. This includes roughly 47,245 patients with early-stage, low-risk breast cancer who are aged 70 and older, highlighting the potential reach and impact of cryoablation as a treatment option.

ProSense® Features and Benefits

The ProSense® Cryoablation System stands out as the first FDA-cleared device for this specific demographic, facilitating a localized treatment option for women who may struggle to undergo traditional surgery. Utilizing liquid nitrogen, ProSense® effectively creates lethal zones to destroy tumor tissue, all while ensuring minimal disruption to surrounding healthy tissue.

This method not only reduces surgical risks but also enhances recovery times, thereby improving the overall patient experience. Furthermore, its portable design allows for office-based procedures, offering convenience for both patients and healthcare practitioners.

Conclusion

The updated ASBrS Resource Guide, favoring cryoablation for low-risk breast cancer patients, represents an encouraging movement towards personalized and less invasive treatments. IceCure Medical's ProSense® system not only aligns with ASBrS’s recommendations but also sets a robust foundation for future developments in breast cancer treatment, aimed at improving patient outcomes and quality of life. As awareness of cryoablation continues to grow, the potential for broader adoption in clinical practice is substantial, encouraging healthier and more informed choices in cancer care.